{
    "id": 21246,
    "cites": 52,
    "cited_by": 1,
    "reference": [
        "Abrams, David, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Did TRIPS spur innovation? An analysis of patent duration and incentives to innovate,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d University of Pennsylvania Law Review, 2009, 157 (6), 1613\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1647.",
        "Acemoglu, Daron and Joshua Linn, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market size in innovation: Theory and evidence from the pharmaceutical industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics, 2004, 119 (3), 1049\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1090.",
        "Aghion, Philippe, Mathias Dewatripont, and Jeremy Stein, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Academic freedom, private-sector focus, and the process of innovation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics, 2008, 39 (3), 617\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c635.",
        "Bessen, James and Eric Maskin, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Sequential innovation, patents, and imitation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics, 2009, 40 (4), 611\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c635.",
        "Blume-Kohout, Margaret and Neeraj Sood, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics, 2013, 97 (1), 327\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c336.",
        "Boldrin, Michele and David K. Levine, Against Intellectual Monopoly, Cambridge University Press, 2008.",
        "Budish, Eric, Benjamin Roin, and Heidi Williams, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Missing markets for innovation: Evidence from new uses of old drugs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2015. MIT mimeo. , , and , \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do firms underinvest in long-term research? Evidence from cancer clinical trials,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, forthcoming.",
        "Cockburn, Iain, Jean Lanjouw, and Mark Schankerman, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patents and the global diffusion of new drugs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2014. National Bureau of Economic Research (NBER) working paper #20492.",
        "Collins, Francis and David Galas, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A new five-year plan for the U.S. Human Genome Project,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Science, 1993, 262 (5130), 43\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c46.",
        ", Ari Patrinos, Elke Jordan, Aravinda Chakravarti, Raymond Gesteland, LeRoy Walters, the members of the DOE, and NIH planning groups, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093New goals for the US Human Genome Project: 1998-2003,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Science, 1998, 282 (5389), 682\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c689.",
        "Cutler, David, Your Money or Your Life: Strong Medicine for America\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Health Care System, Oxford University Press, 2004. Dubois, Pierre, Olivier de Mouzon, Fiona Scott Morton, and Paul Seabright, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market size and pharmaceutical innovation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics, forthcoming.",
        "Duggan, Mark, Craig Garthwaite, and Aparajita Goyal, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The market impacts of pharmaceutical product patents in developing countries: Evidence from India,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2014. National Bureau of Economic Research (NBER) working paper #20548.",
        "Finkelstein, Amy, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Static and dynamic effects of health policy,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics, 2004, 119 (2), 527\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c567.",
        "Furman, Jeffrey and Scott Stern, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Climbing atop the shoulders of giants: The impact of institutions on cumulative research,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 2011, 101 (5), 1933\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1963. Galasso, Alberto and Mark Schankerman, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patents and cumulative innovation: Causal evidence from the courts,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics, forthcoming.",
        "Gilbert, Richard and Carl Shapiro, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Optimal patent length and breadth,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics, 1990, 21, 106\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c112.",
        "Giorcelli, Michela and Petra Moser, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Copyrights and creativity: Evidence from Italian operas,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2015. unpublished Stanford mimeo.",
        "Heller, Michael and Rebecca Eisenberg, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Can patents deter innovation? The anticommons in biomedical research, \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Science, 1998, 280 (5364), 698\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c701.",
        "Hemphill, C Scott and Bhaven Sampat, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Evergreening, patent challenges, and effective market life in pharmaceuticals, \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics, 2011, 31 (2), 327\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c339.",
        "Istrail, Sorin et al., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Whole-genome shotgun assembly and comparison of human genome assemblies,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Proceedings of the National Academy of Sciences, 2004, 101 (7), 1916\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1921.",
        "Jaffe, Adam, Manuel Trajtenberg, and Rebecca Henderson, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Geographic localization of knowledge spillovers as evidenced by patent citations,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics, 1993, 108 (3), 577\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c598.",
        "Kaplow, Louis, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The patent-antitrust intersection: A reappraisal,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Harvard Law Review, 1984, 97, 1815\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1892.",
        "Kesselheim, Aaron, Robert Cook-Deegan, David Winickoff, and Michelle Mello, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Gene patenting - The Supreme Court finally speaks,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine, 2013, 369 (9), 869\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c875.",
        "Klemperer, Paul, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How broad should the scope of patent protection be?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics, 1990, 21, 113\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c130.",
        "Kyle, Margaret and Anita McGahan, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Investments in pharmaceuticals before and after TRIPS,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Review of Economics and Statistics, 2012, 94 (4), 1157\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1172.",
        "Lander, Eric et al., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Initial sequencing and analysis of the human genome,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Nature, 2001, 409 (6822), 860\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c921.",
        "Lathia, CD, D Amakye, W Dai, C Girman, S Madani, J Mayne, P MacCarthy, P Pertel, L Seman, A Stoch, P Tarantino, C Webster, S Williams, and JA Wagner, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The value, qualification, and regulatory use of surrogate end points in drug development,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Clinical Pharmacology & Therapeutics, 2009, 86 (1), 32\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c43.",
        "Lerner, Joshua, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The empirical impact of intellectual property rights on innovation: Puzzles and clues,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review Papers and Proceedings, 2009, 99 (2), 343\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c348.",
        "Marshall, Eliot, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Lock up the genome, lock down research,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Science, 2013, 342, 72\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c73.",
        "Meyskens, Frank, Gregory Curt, Dean Brenner, Gary Gordon, Ronald Herberman, Olivera Finn, Gary Kelloff, Samir Khleif, Caroline Sigman, and Eva Szabo, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Regulatory approval of cancer risk-reducing (chemopreventive) drugs: Moving what we have learned into the clinic,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Cancer Prevention Research, 2011, 4 (3), 311\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c323.",
        "Moser, Petra, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How do patent laws influence innovation? Evidence from nineteenth-century world\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s fairs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 2005, 95 (4), 1214\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1236.",
        ", Joerg Ohmstedt, and Paul Rhode, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patent citations and the size of innovation: Evidence from hybrid corn,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2014. unpublished Stanford mimeo.",
        "Murray, Fiona and Scott Stern, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do formal intellectual property rights hinder the free flow of scientific knowledge ? An empirical test of the anti-commons hypothesis,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Behavior and Organization, 2007, 63 (4), 648\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c687.",
        ", Philippe Aghion, Mathias Dewatripont, Julian Kolev, and Scott Stern, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Of mice and academics: Examining the effect of openness on innovation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2008. unpublished MIT mimeo.",
        "Nordhaus, William, Invention, Growth, and Welfare: A Theoretical Treatment of Technological Change, MIT Press, 1969.",
        "Ouellette, Lisa Larrimore, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patent experimentalism,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Virginia Law Review, forthcoming. Pennisi, Elizabeth, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Human genome: Academic sequencers challenge Celera in a sprint to the finish,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Science, 1999, 283 (5409), 1822\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1823.",
        "Psaty, Bruce, Noel Weiss, Curt Furberg, Thomas Koepsell, David Siscovick, Frits Rosendaal, Nicholas Smith, Susan Heckbert, Robert Kaplan, Danyu Lin, Thomas Fleming, and Edward Wagner, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of the American Medical Association, 1999, 282 (8), 786\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c790.",
        "Sakakibara, Mariko and Lee Branstetter, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do stronger patents induce more innovation? Evidence from the 1988 Japanese patent law reforms,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics, 2001, 32 (1), 77\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c100.",
        "Sampat, Bhaven and Heidi Williams, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How do patents affect follow-on innovation? Evidence from the human genome,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2015. MIT mimeo.",
        "Scherer, F.M., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Nordhaus\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 theory of optimal patent life: A geometric reinterpretation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 1972, 62 (3), 422\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c427.",
        "Science Online, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Accessing the Celera human genome sequence data,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2001. http://www.sciencemag.org/ feature/data/announcement/gsp.dtl (last accessed 21 December 2011).",
        "Scotchmer, Suzanne, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Standing on the shoulders of giants: Cumulative research and the patent law,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Perspectives, 1991, 5 (1), 29\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c41.",
        ", \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Protecting early innovators: Should second-generation products be patentable?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics, 1996, 27 (2), 322\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c331.",
        "Service, Robert, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Can data banks tally profits?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Science, 2001, 291 (5507), 1203.",
        "Shreeve, James, The Genome War: How Craig Venter Tried to Capture the Code of Life and Save the World, Ballantine Books, 2005.",
        "Venter, J. Craig et al., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The sequence of the human genome,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Science, 2001, 291 (5507), 1304\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1351.",
        ", Mark Adams, Granger Sutton, Anthony Kerlavage, Hamilton Smith, and Michael Hunkapiller, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Shotgun sequencing of the human genome,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Science, 1998, 280 (5369), 1540\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1542.",
        "Wade, Nicholas, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Once again, scientists say human genome is complete,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New York Times, 2003, 15 April. Waldfogel, Joel, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Copyright protection, technological change, and the quality of new products: Evidence from recorded music since Napster,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics, forthcoming.",
        "Walsh, John, Ashish Arora, and Wesley Cohen, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Working through the patent problem,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Science, 2003, 299 (5609), 1021.",
        "Weisfelt, Myron and Susan Zieman, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Advances in the prevention and treatment of cardiovascular disease,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs, 2007, 26 (1), 25\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c37.",
        "Williams, Heidi, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Intellectual property rights and innovation: Evidence from the human genome,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy, 2013, 121 (1), 1\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c27.",
        "Yin, Wesley, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market incentives and pharmaceutical innovation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics, 2008, 27 (4), 1060\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1077.",
        ", \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093R&D policy, agency costs and innovation in personalized medicine,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics, 2009, 28 (5), 950\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c962."
    ]
}